Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.22T
24h Vol:
$9.44B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  CVM
CEL-SCI
CVM
49 / 100
Penny Stock
$1.45arrow_drop_down3.64%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$1.51
Prev. Close$1.51
EPS-0.69
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap82048384.00
PE Ratio-
LOWHIGH
Day Range1.44
1.53
52 Week Range1.04
3.23
Ratios
P/B Ratio6.96
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %12.28%
EBITDA Margin %-
ROE %-158.25%
EPS-0.69

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

49vs 54. Market Avg.

All Score 49 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

CVMMARKET
Value6840
Quality2240
Ownership717
Growth5847
Dividends-38
check_circle

CEL-SCI's Price discount from all time high of 99.99% is great compared to market average of 42.83%. This indicates CVM could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$745.69
24H (%)arrow_drop_up1.96%
24H ($)$14.35
MARKET CAP$695.32B
PRICE$486.17
24H (%)arrow_drop_down1.02%
24H ($)-$5.05
MARKET CAP$452.88B
PRICE$149.56
24H (%)arrow_drop_up0.29%
24H ($)$0.44
MARKET CAP$359.34B
PRICE$126.88
24H (%)arrow_drop_down0.04%
24H ($)-$0.06
MARKET CAP$321.54B

About CEL-SCI (CVM)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Sector
Healthcare
Industry
Biotechnology
CEO
-
Headquarters
Vienna
Employees
0
Exchange
NYSE
add CEL-SCI to watchlist

Keep an eye on CEL-SCI

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is CEL-SCI's (CVM) price per share?

The current price per share for CEL-SCI (CVM) is $1.47. The stock has seen a price change of -$0.06 recently, indicating a -3.64% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for CEL-SCI (CVM)?

For CEL-SCI (CVM), the 52-week high is $3.23, which is 121.99% from the current price. The 52-week low is $1.04, the current price is 39.9% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is CEL-SCI (CVM) a growth stock?

CEL-SCI (CVM) has shown an average price growth of -47.6% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CEL-SCI as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is CEL-SCI (CVM) stock price performance year to date (YTD)?

As of the latest data, CEL-SCI (CVM) has a year-to-date price change of -45.3%. Over the past month, the stock has experienced a price change of -11.79%. Over the last three months, the change has been -45.51%. Over the past six months, the figure is -3.32%. Looking at a longer horizon, the five-year price change stands at -77.95%.

help
Is CEL-SCI (CVM) a profitable company?

CEL-SCI (CVM) has a net income of -$32.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$31.48M. Furthermore, the EBITDA is -$28.14M.

help
What is the market capitalization of CEL-SCI (CVM)?

CEL-SCI (CVM) has a market capitalization of $82.05M. The average daily trading volume is 165.86K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.